A Phase 3 clinical trial investigating different surgical approaches for Stage IA Non-Small Cell Lung Cancer reached primary completion on 2025-09-30. The study enrolled 701 participants to compare surgical techniques.
Background
For patients with Stage IA Non-Small Cell Lung Cancer, surgical intervention is a primary treatment. The trial's rationale highlights that less invasive surgical options, such as wedge resection or segmentectomy, may offer advantages over lobectomy, including fewer side effects and improved recovery. However, the comparative effectiveness of these different surgical approaches for treating Stage IA non-small cell lung cancer has not been definitively established. This trial aims to provide clarity on which surgical method offers the best outcomes for these patients.
Trial design
This randomized Phase 3 trial enrolled 701 participants with Lung Cancer, specifically Stage IA Non-Small Cell Lung Cancer. The study's purpose is to compare how well different types of surgery work in treating these patients. The trial investigates wedge resection or segmentectomy as potentially less invasive options compared to lobectomy.
What this means
The primary completion of this Phase 3 trial signifies that the main data collection phase has concluded. The study aims to determine whether less invasive surgical procedures like wedge resection or segmentectomy are as effective as lobectomy for patients with Stage IA Non-Small Cell Lung Cancer. The findings from this trial could potentially inform future surgical guidelines, offering patients options that may lead to fewer side effects and faster recovery while maintaining efficacy.
Source
Information regarding the primary completion of this clinical trial was obtained from ClinicalTrials.gov, a public database of clinical studies. The record for study NCT00499330, titled "Comparison of Different Types of Surgery in Treating Patients With Stage IA Non-Small Cell Lung Cancer," was updated on 2025-09-30 on clinicaltrials.gov.